
Omeros Corporation (NASDAQ:OMER – Free Report) – Research analysts at HC Wainwright boosted their FY2027 earnings estimates for shares of Omeros in a research report issued on Tuesday, November 17th. HC Wainwright analyst B. Folkes now anticipates that the biopharmaceutical company will earn $0.33 per share for the year, up from their previous forecast of $0.24. HC Wainwright has a “Buy” rating and a $33.00 price objective on the stock. The consensus estimate for Omeros’ current full-year earnings is ($0.37) per share.
Omeros (NASDAQ:OMER – Get Free Report) last issued its quarterly earnings data on Monday, November 16th. The biopharmaceutical company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.04. The company had revenue of $35.93 million for the quarter, compared to analyst estimates of $37.28 million.
Read Our Latest Stock Report on Omeros
Omeros Trading Down 16.5%
Omeros stock opened at $13.92 on Wednesday. Omeros has a 12 month low of $6.70 and a 12 month high of $21.24. The stock’s 50 day moving average is $18.12 and its 200-day moving average is $13.77. The company has a market capitalization of $1.01 billion, a price-to-earnings ratio of 14.50 and a beta of 2.96.
Insider Buying and Selling at Omeros
In other Omeros news, CAO David Borges sold 10,000 shares of the stock in a transaction that occurred on Wednesday, September 23rd. The shares were sold at an average price of $20.95, for a total transaction of $209,500.00. Following the transaction, the chief accounting officer owned 5,000 shares in the company, valued at $104,750. This represents a 66.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Peter Cancelmo sold 25,000 shares of the firm’s stock in a transaction that occurred on Monday, August 31st. The stock was sold at an average price of $18.54, for a total transaction of $463,500.00. Following the transaction, the vice president directly owned 200 shares in the company, valued at $3,708. This represents a 99.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 100,906 shares of company stock worth $1,904,955. 10.50% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On Omeros
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Sterling Capital Management LLC lifted its position in shares of Omeros by 75.3% during the 3rd quarter. Sterling Capital Management LLC now owns 1,764 shares of the biopharmaceutical company’s stock valued at $34,000 after acquiring an additional 758 shares during the period. Assetmark Inc. bought a new position in shares of Omeros in the first quarter worth $38,000. GK Wealth Management LLC bought a new position in shares of Omeros in the third quarter worth $65,000. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Omeros in the third quarter worth $70,000. Finally, Parallel Advisors LLC raised its stake in Omeros by 778.1% in the third quarter. Parallel Advisors LLC now owns 6,586 shares of the biopharmaceutical company’s stock valued at $125,000 after purchasing an additional 5,836 shares in the last quarter. 48.79% of the stock is owned by institutional investors and hedge funds.
Top Omeros Stories
Investors following OMER have been watching these stories:
- Positive Sentiment: YARTEMLEA, Omeros’s approved treatment for transplant-associated thrombotic microangiopathy, generated $41.8 million in gross sales. Sales rose 26% sequentially, signaling continued commercial growth. Why Is Omeros Stock Trading Lower Tuesday?
- Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $33 price target, indicating substantial potential upside in the firm’s view. HC Wainwright stock recommendations
- Negative Sentiment: Revenue was $35.9 million, below the roughly $37.3 million analyst estimate. Reports also pointed to a wider quarterly loss and setbacks in Europe, tempering the earnings beat and sales growth. Omeros Shares Down on Wider 3Q Loss
About Omeros
Omeros Corporation (NASDAQ: OMER) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for disorders involving the complement, immune and coagulation systems. The company has also developed a pipeline of investigational therapies aimed at treating serious diseases involving complement activation and immune-system dysfunction. The company is headquartered in Seattle, Washington, and was founded in 1994. Its leading investigational programs have included narsoplimab, which targets the lectin pathway of the complement system, and OMS906, an antibody designed to inhibit MASP-3 and regulate the alternative pathway.
See Also
- Five stocks we like better than Omeros
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.
